Can a simple drug calm catatonia in autistic teens? new study hopes so

NCT ID NCT07498387

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tests whether benzodiazepines (midazolam and clonazepam) and, if needed, electroconvulsive therapy (ECT) can safely reduce catatonic symptoms in 30 adolescents aged 10–19 with profound autism. Participants first receive a midazolam challenge; those who respond then take daily clonazepam for up to 3 months. The main goal is to see if symptoms improve significantly without major side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Midazolam and Clonazepam (benzodiazepines)
What this could lead to
If it works, this could point toward a safe, effective way to manage catatonic episodes in teens with profound autism, improving their daily functioning.
What could go wrong
This is a very small, early pilot study with only 30 participants and no control group, so results may not apply broadly. Benzodiazepines can cause sedation or dependence.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTISM SPECTRUM DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Child and Adolescent Psychiatry Clinics, Psychiatry and Neurology Center, Tanta University

    Tanta, El-Gharbia Governorate, 31527, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.